ATLANYS
Dead · Cancelled DEAD/REGISTRATION/Cancelled/Invalidated
What this record means
The record shows that ATLANYS is no longer active – it was cancelled on Nov 15 2024 after the underlying International Registration was declared dead, and the U.S. registration on the Principal Register was terminated. The owner listed is NOVARTIS AG, a Swiss Aktiengesellschaft, and the mark was limited to Class 005 covering a long list of pharmaceutical products such as anti‑infectives, anti‑inflammatories, cardiovascular and dermatological medicines, among many others. Because the protection was confined to those pharmaceutical goods, a similar name used for unrelated services (for example, software or apparel) would be far removed from the scope shown here, though a pharma‑related use could raise a meaningful concern. The record contains no opposition, cancellation or court actions, so no enforcement signal appears. I'd treat this as a notable risk if you plan a name in the same drug‑product space, but it doesn’t block every possible use of the word.
Informational only - not legal advice.Mark Trademark
| Drawing type | 4 - STANDARD CHARACTER MARK |
| Filing basis | Madrid Protocol (§66(a)). |
| Status | U.S. registration cancelled because International Registration cancelled in whole or in part. |
Key dates
| Application filed | Dec 12, 2018 |
| Published for opposition | Apr 23, 2019 |
| Registered (Principal) | Jul 09, 2019 |
| Status date | Nov 15, 2024 |
Goods & services
Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for ophthalmological use; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma
Madrid Protocol · §66(a)
| Intl. registration no. | 1266015 |
| Intl. registration date | Aug 10, 2015 |
| Intl. renewal date | Aug 10, 2035 |
| Date of automatic protection | Aug 21, 2020 |
| Notification of designation | Feb 21, 2019 |
| First refusal flag | No |
Owner & representation
| Owner | NOVARTIS AG |
| Address | CH-4002 Basel, SWITZERLAND |
| Entity | Aktiengesellschaft - organized in SWITZERLAND |
| Attorney of record | |
| Correspondent | Novartis Pharma AG, |
| Correspondent address | Postfach, CH-4002 |